Bill Caldwell, Chairman and CEO of Advanced Cell Technology, tells Proactive Investors that while the stem cell company is on the verge of major breakthroughs he is confident it has sufficient cash to get through the next two years. He is also encouraged by the high trading volumes in ACTC stock and says this, combined with the stock price, represents nothing more than an option with no expiration date for investors.
